4 active not recruiting, 4 recruiting, 1 completed, 1 terminated. 8 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 4, Active not recruiting 3, Withdrawn 1 |
| Phase 2 | 7 | Recruiting 3, Active not recruiting 1, Completed 1, Terminated 1, Withdrawn 1 |
Follow Recurrent Mixed Phenotype Acute Leukemia: new trials by email Literature Review of Recurrent Mixed Phenotype Acute Leukemia trials Research Report on Recurrent Mixed Phenotype Acute Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane Cytarabine, Fludarabine, Leucovorin - Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2023-10-10 | 2026-06-02 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 20 | 2022-09-02 | 2026-05-06 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2019-07-10 | 2026-06-22 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome Decitabine, Laboratory Biomarker Analysis, Venetoclax - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 235 | 2018-01-18 | 2026-03-10 |
| Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 28 | 2017-10-25 | 2026-08-20 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 75 | 2017-10-24 | 2026-06-22 |
| Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Clofarabine, Cytarabine, Dexamethasone - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 16 | 2014-10-27 | 2024-03-22 |
Leukemia, Biphenotypic, Acute (11) · Leukemia, Myeloid, Acute (7) · Leukemia, Myelomonocytic, Chronic (5) · Myelodysplastic Syndromes (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Burkitt Lymphoma (3) · Anemia, Refractory, with Excess of Blasts (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Blast Crisis (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Juvenile (1)
Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Leukemia (10) · Leukemia, Lymphoid (10) · Leukemia, Myeloid (7) · Bone Marrow Diseases (6) · Chronic Disease (5) · Disease Attributes (5) · Lymphoma (5)
Biopsy (5) · Cytarabine (5) · Specimen Handling (4) · fludarabine phosphate (4) · Injections (3) · Methotrexate (3) · Whole-Body Irradiation (3) · merphos (3) · CT-P10 (2) · Decitabine (2) · Hydrocortisone (2) · Idarubicin (2) · Methylprednisolone (2) · Mycophenolic Acid (2) · N,N-dicyclohexyl-isoborneol-10-sulfonamide (2)
Fred Hutchinson Cancer Center (4) · Children's Oncology Group (2) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · OHSU Knight Cancer Institute (1)
United States (10) · Canada (1)
Abhishek Maiti, MBBS (1) · Brenda M. Sandmaier (1) · Elias Jabbour (1) · Elizabeth Krakow (1) · Ivana Gojo (1) · Jessica T Leonard (1) · Kelly E Faulk (1) · Maria Luisa Sulis (1) · Matthew A Kutny (1) · Naveed Ali, MD (1) · Phuong Vo (1)
PMID 30335787, PMID 32896301, PMID 33027528, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 35622074, PMID 38683966
P01CA078902 (2), U10CA180886 (2), P30CA015704 (1), UM1CA186691 (1), UM1CA228823 (1)